Tag: CKM
-
The three-pillar combination in CKM — where the finerenone + SGLT2i + GLP-1 case is proven, and where it is still an assumption
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. The “three-pillar” combination in cardio-kidney-metabolic (CKM) disease stacks three non-overlapping mechanisms — SGLT2 inhibitor (hemodynamic), GLP-1 receptor agonist (metabolic) and finerenone (anti-inflammatory / anti-fibrotic). CONFIDENCE (NEJM…
-
The finerenone landscape — a nonsteroidal MRA as the third pillar of CKM care, and what is still an open question
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that targets inflammation and fibrosis rather than blood pressure and volume — a mechanism that does not overlap…
-
Do incretins move hard outcomes in CKM, not just weight? A close read of SELECT, FLOW and SUMMIT
This article has been superseded. An expanded and updated version was published on 25 July 2026 and is now the version of record. Read the current version → Whether GLP-1 receptor agonists improve hard cardiovascular and kidney outcomes in cardio-renal-metabolic disease, rather than weight alone — read against the SELECT, FLOW and SUMMIT trials. The…
-
The GLP-1 / incretin landscape — why the question moved from “how much weight?” to “what does it change?”
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. The incretin (GLP-1) class is expanding beyond glucose and weight into cardiovascular, kidney and heart-failure indications. In the only two head-to-head trials, the dual agent (tirzepatide)…
-
The asymmetry in the US cardiovascular-kidney-metabolic standard — widen the diagnosis, narrow the drug threshold
Evidence-first notes on bioscience and medical affairs, at the edge of the clinic and the market. Information only — not investment advice, not medical advice. The 30-second version What. The four US “definition-setting” societies (AHA, ACC, ADA, ASN) have converged on a single Cardiovascular-Kidney-Metabolic (CKM) syndrome frame that ties heart, kidney and metabolism together, and…
-
Who names the disease — America’s CKM and Europe’s SMD, two axes of definitional power over metabolic disease
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Two upper-level disease taxonomies are competing over the cardio-renal-metabolic continuum. In the United States, the AHA-led CKM (Cardiovascular-Kidney-Metabolic) Syndrome (2023 advisory → 2026 multisociety guideline).…
Uthando Nethemba 